In this paper we consider patients of NSCLC or metastatic melanoma who are treated with CTLA-4 inhibitor (ipilimumab), and thus are at risk of severe adverse events, such as permanent damage to a vital organ. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.